Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofadil in Acute Ischemic Stroke
NCT04453800Phase 2Completed
- Sponsor
- Peking University Third Hospital
- Start
- Oct 2016
- Primary completion
- Jan 2018
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of diltiazem in ischemic stroke (4 arms), sponsored by Peking University Third Hospital. Primary endpoint: National Institutes of Health Stroke Scale at 14 days. Started Oct 2016; status: completed.
02
Drugs
diltiazem
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04453800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04453800.